---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-25-000059"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:14:07.042464+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62

## Summary
- Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.
- TAVR sales $1.15B (+12.4%); TMTT sales $145.2M (+59.3%).
- Raised FY2025 adjusted EPS guidance to $2.56-$2.62 from high end of $2.45-$2.55.
- Raised TAVR sales growth guidance to 7-8% from 6-7%; total sales growth to high end of 9-10%.
- Board increased share repurchase authorization to $2.1B.

## SEC filing metadata
- accession: 0001099800-25-000059
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/0001099800-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980025000059/ew-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-25-000059
- JSON: https://secwatch.observer/filing/0001099800-25-000059.json
- Plain text: https://secwatch.observer/filing/0001099800-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.